Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bezafibrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 101Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Intercept: OCA-Bezafibrate Combo Data In PBC At EASL 2024
    Intercept: OCA-Bezafibrate Combo Data In PBC At EASL 2024

    05 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/05/2894098/23024/en/Intercept-Presents-New-Data-on-the-Results-of-OCA-Bezafibrate-Combination-Therapy-in-PBC-After-Six-Months-of-Treatment-in-Late-Breaking-Poster-Presentation-at-EASL-Congress-2024.html

    GLOBENEWSWIRE
    05 Jun 2024
    Share Share
    Intercept Shows OCA-Bezafibrate Combo Impact On ALP, Metabolic Outcomes
    Intercept Shows OCA-Bezafibrate Combo Impact On ALP, Metabolic Outcomes

    18 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/18/2884546/23024/en/Intercept-Presents-New-Data-Demonstrating-the-Impact-of-OCA-Bezafibrate-Combination-Therapy-on-ALP-and-Metabolic-Outcomes-After-Six-Months-of-Treatment-at-Digestive-Disease-Week-20.html

    GLOBENEWSWIRE
    18 May 2024
    Share Share
    Intercept Announces Phase 2 Data Showing Significant Impact of OCA-Bezafibrate
    Intercept Announces Phase 2 Data Showing Significant Impact of OCA-Bezafibrate

    13 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/13/2779021/23024/en/Intercept-Announces-New-Phase-2-Data-Showing-Significant-Impact-of-OCA-Bezafibrate-Combination-on-Normalization-of-Multiple-Key-Biomarkers-of-PBC-Induced-Liver-Damage-at-AASLD-The-.html

    GLOBENEWSWIRE
    13 Nov 2023
    Share Share
    Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate
    Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate

    23 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/23/2693415/23024/en/Intercept-Presents-New-Data-Showing-Significant-Impact-of-OCA-bezafibrate-Combination-on-Normalization-of-Multiple-Biomarkers-of-PBC-Induced-Liver-Damage.html

    GLOBENEWSWIRE
    23 Jun 2023
    Share Share
    Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA
    Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA

    07 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/07/2683624/23024/en/Intercept-Announces-New-Data-Showing-Potential-of-Fixed-Dose-Combination-of-OCA-and-Bezafibrate-to-Normalize-Multiple-Biomarkers-in-PBC-to-be-Featured-in-Podium-Presentation-at-EAS.html

    GLOBENEWSWIRE
    07 Jun 2023
    Share Share
    Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate
    Intercept Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate

    11 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/11/2440783/23024/en/Intercept-Announces-First-Patient-Dosed-in-Phase-2-Study-of-OCA-and-Bezafibrate-for-the-Treatment-of-Primary-Biliary-Cholangitis.html

    GLOBENEWSWIRE
    11 May 2022
    Share Share